Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma

AIDS
Silvia MontotoKate Cwynarski

Abstract

: To retrospectively describe the recovery of cellular immunity and the clinical outcome of 30 patients with HIV-associated Burkitt's lymphoma (HIV-BL), who were treated with the intensive chemotherapy CODOX-M/IVAC and HAART as part of their standard care. : Seventy-three percent of the patients had high-risk disease, defined by stage, performance status, extranodal sites and lactate dehydrogenase. The median CD4 cell count at diagnosis of HIV-BL was 171/ml (range: 4-848) and the plasma HIV viral load was undetectable in five of 29 patients. : Nine patients died during treatment (disease progression, three; toxicity, five; central nervous system lesion not biopsied, one). Response rate was 70% (complete response/complete response uncertain, 17; partial response, 4). After a median follow-up of 22 months (range: 6-72), 18 patients remain alive without disease progression. The 3-year overall survival and event-free survival were 52 and 75%, respectively. Viral load was undetectable in 88% and CD4 cell count more than 200/ml in 58% of patients assessed 6 months after completing chemotherapy, and in 87 and 80% at 12 months, respectively. : The intensive regimen CODOX-M/IVAC, a feasible and effective chemotherapy, is associated with...Continue Reading

References

Dec 10, 1996·AIDS Research and Human Retroviruses·S ZanussiP De Paoli
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Jun 2, 2001·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·J O BalzerG Biamino
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alessandro ReMaurizio Mazzuccato
Jul 9, 2004·Blood·Mark BowerJustin Stebbing
Mar 23, 2005·Experimental Hematology·David SerranoUNKNOWN Spanish Cooperative Groups GELTAMO and GESIDA
Aug 19, 2008·HIV Medicine·M BowerUNKNOWN AIDS Malignancy Subcommittee

❮ Previous
Next ❯

Citations

Nov 15, 2013·The New England Journal of Medicine·Kieron DunleavyWyndham H Wilson
Jul 31, 2013·Journal of the National Cancer Institute·Satish GopalKristy L Richards
Dec 10, 2013·Hematology·Richard F Little, Kieron Dunleavy
Apr 24, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Satish GopalJoseph J Eron
Aug 29, 2012·British Journal of Haematology·Andrés J M FerreriAlessandro Re
Jan 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S K BartaJ A Sparano
Mar 24, 2011·International Journal of STD & AIDS·H Woodcock, M Nelson
Aug 31, 2019·British Journal of Haematology·Laure PhilippeUNKNOWN ANRS-CO16 LYMPHOVIR Cohort
Jun 1, 2017·International Journal of Hematologic Oncology·José-Tomás Navarro, Josep-Maria Ribera
Oct 21, 2016·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Xuesong HanChristopher R Flowers
Aug 28, 2021·Cancers·Julius Maximilian KnerrMette Marie Rosenkilde

❮ Previous
Next ❯

Related Concepts

Related Feeds

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.